BioArctic Dirección

Dirección controles de criterios 3/4

El CEO de BioArctic's es Gunilla Osswald , nombrado en Jan 2014, tiene una permanencia de 10.25 años. compensación anual total es SEK22.38M, compuesta por 19.8% salario y 80.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de SEK18.67M. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 10.4 años, respectivamente.

Información clave

Gunilla Osswald

Chief Executive Officer (CEO)

kr22.4m

Compensación total

Porcentaje del salario del CEO	19.8%
Permanencia del CEO	10.3yrs
Participación del CEO	0.1%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	10.5yrs

Actualizaciones recientes de la dirección

Recent updates

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

Apr 13

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 19

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 03

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Dec 23

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Nov 12

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Jul 21

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Jul 15

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Jul 07

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

May 06

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Mar 13

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Nov 30

BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate

Sep 15

BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business

Aug 23

Is BioArctic AB (publ) (STO:BIOA B) Trading At A 41% Discount?

Jun 03

Shareholders Will Probably Not Have Any Issues With BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation

Apr 29

Is BioArctic's (STO:BIOA B) Share Price Gain Of 291% Well Earned?

Mar 14

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gunilla Osswald en comparación con los beneficios de BioArctic?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	kr22m	kr4m	kr229m
Sep 30 2023	n/a	n/a	kr259m
Jun 30 2023	n/a	n/a	kr270m
Mar 31 2023	n/a	n/a	kr327m
Dec 31 2022	kr9m	kr5m	-kr11m
Sep 30 2022	n/a	n/a	kr28m
Jun 30 2022	n/a	n/a	-kr147m
Mar 31 2022	n/a	n/a	-kr135m
Dec 31 2021	kr5m	kr3m	-kr120m
Sep 30 2021	n/a	n/a	-kr114m
Jun 30 2021	n/a	n/a	-kr97m
Mar 31 2021	n/a	n/a	-kr101m
Dec 31 2020	kr5m	kr3m	-kr69m
Sep 30 2020	n/a	n/a	-kr72m
Jun 30 2020	n/a	n/a	-kr60m
Mar 31 2020	n/a	n/a	kr78m
Dec 31 2019	kr7m	kr3m	kr88m
Sep 30 2019	n/a	n/a	kr441m
Jun 30 2019	n/a	n/a	kr475m
Mar 31 2019	n/a	n/a	kr380m
Dec 31 2018	kr5m	kr3m	kr382m
Sep 30 2018	n/a	n/a	kr58m
Jun 30 2018	n/a	n/a	kr32m
Mar 31 2018	n/a	n/a	kr29m
Dec 31 2017	kr3m	kr2m	kr15m

Compensación vs. Mercado: La compensación total de Gunilla($USD2.05M) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD790.54K).

Compensación vs. Ingresos: La compensación de Gunilla ha sido consistente con los resultados de la empresa en el último año.

CEO

Gunilla Osswald (62 yo)

10.3yrs

Permanencia

kr22,378,000

Compensación

Dr. Gunilla Osswald, PhD has been the Chief Executive Officer and President of BioArctic AB (publ) since 2014. Dr. Osswald has been a Director of Egetis Therapeutics AB (publ) (formerly known as PledPharma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gunilla Osswald	President & CEO	10.3yrs	kr22.38m	0.11% SEK 19.2m
Pär Gellerfors	Co-Founder	21.3yrs	kr390.00k	0% SEK 0
Lars Lannfelt	Co-Founder	21.3yrs	kr2.54m	33.43% SEK 6.0b
Anders Martin-Lof	Chief Financial Officer	less than a year	sin datos	sin datos
Johanna Fälting	Chief Research Officer & Head of Research	no data	sin datos	0.054% SEK 9.7m
Christer Möller	VP of Pre-Clinical Development & Chief Scientific Officer	18.3yrs	sin datos	0.063% SEK 11.3m
Oskar Bosson	VP and Head of IR & Communication	4yrs	sin datos	0.012% SEK 2.1m
Leif Gallo	General Counsel and Head of Legal & IP	no data	sin datos	sin datos
Harald Borgeke	Head of Public Affairs	2.1yrs	sin datos	sin datos
Frida Lekander	Head of Marketing	2.3yrs	sin datos	sin datos
Gunilla Andersson	Vice President of Human Resources	5.3yrs	sin datos	sin datos
Mikael Moge	VP & Head of CMC	no data	sin datos	0.011% SEK 1.9m

5.3yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BIOA B es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pär Gellerfors	Co-Founder	21.3yrs	kr390.00k	0% SEK 0
Lars Lannfelt	Co-Founder	21.3yrs	kr2.54m	33.43% SEK 6.0b
Eugen Steiner	Independent Chairman	6.7yrs	kr621.00k	0.091% SEK 16.2m
Hans Wigzell	Member of Scientific Advisory Board	no data	sin datos	sin datos
Konrad Beyreuther	Member of the Scientific Board	no data	sin datos	sin datos
Mikael Smedeby	Independent Director	6yrs	kr316.00k	0.031% SEK 5.5m
Ivar Verner	Independent Vice Chairman	14.3yrs	kr406.00k	0.14% SEK 24.9m
Charlotta Ljungqvist	Independent Director	3yrs	kr318.00k	0.0036% SEK 641.9k
Martin Ingelsson	Member of Scientific Board	no data	sin datos	sin datos
Staffan Pauli	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ken Marek	Member of Scientific Advisory Board	no data	sin datos	sin datos
Kaj Blennow	Member of Scientific Advisory Board	no data	sin datos	sin datos

10.5yrs

Permanencia media

74yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de BIOA B son experimentados ( 10.4 años antigüedad media).

BioArctic Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Vice President of Human Resources exercised options to buy kr1.2m worth of stock.

Independent Chairman recently bought kr1.1m worth of stock

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research exercised options to buy kr1.2m worth of stock.

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Recent updates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Consensus EPS estimates increase by 112%

Vice President of Human Resources exercised options to buy kr1.2m worth of stock.

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 15%

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Consensus revenue estimates fall by 16%

Consensus revenue estimates fall by 14%

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research exercised options to buy kr1.2m worth of stock.

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Consensus revenue estimates increase by 13%

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Consensus revenue estimates increase by 12%

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Now 21% undervalued

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Independent Director recently sold kr3.3m worth of stock

Price target increased by 12% to kr400

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Consensus EPS estimates fall by 60%

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

Consensus forecasts updated

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Consensus forecasts updated

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released: EPS: kr1.55 (vs kr0.43 loss in 3Q 2021)

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn

Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic)

Price target increased to kr266

Consensus estimates of losses per share improve by 35%

Second quarter 2022 earnings released: kr0.52 loss per share (vs kr0.39 loss in 2Q 2021)

Independent Deputy Chairman recently bought kr412k worth of stock

Insider recently bought kr100k worth of stock

First quarter 2022 earnings: Revenues miss analyst expectations

Price target increased to kr238

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow

Independent Deputy Chairman recently bought kr824k worth of stock